Pour Demain submitted a joint contribution with 14 co-signees to the European Commission’s Call for Evidence on the EU Biotech Act, alongside colleagues from academia, industry, and civil society. Our recommendations show how embedding biosecurity into EU biotech governance can strengthen innovation, bolster strategic autonomy, and build a high-trust bioeconomy.

The following is a fictional short-story about a remote third-party general purpose AI audit, occurring within the EU in the year 2028....

Pour Demain hat in Zusammenarbeit mit Blueprint Biosecurity und RAND Europe Feedback zu zwei wichtigen EU-Konsultationen eingereicht: zur...

The following is an excerpt of an op-ed published by Pour Demain in Tech Policy Press . The article provides nuance to the innovation vs...

Current geopolitical tensions and rapid technological developments have necessitated an urgent reassessment of biological risks and their...

Medical diagnostics, biomanufacturing, and many other parts of the bioeconomy rely on synthetic nucleic acids (NAs). Clinicians and...

Während sich die Europäische Union auf die Umsetzung des KI-Gesetzes vorbereitet, ist die Sicherstellung robuster Evaluierungsmethoden...

Biotech: Ensure safety to maximise progress. Safeguards needed for responsible innovation.

In an era where General Purpose AI (GPAI) models are becoming increasingly prevalent and powerful, the need for robust incident reporting...

Fern-UVC-Licht kann dazu beitragen, um saisonale Krankheiten und künftige Pandemien effektiv zu bekämpfen. Eine neue Studie von d-fine...